11.15USD-1.59%Mkt Cap: 890.08M USDP/E: —Last update: 2026-05-26
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III cli…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap890.08M USD
Enterprise Value1.29B USD
Revenue (TTM)204.89M USD
Gross Profit152.51M USD
Net Income (TTM)-221.25M USD
Revenue/Share2.716 USD
Last Price11.15 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees371
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)8.05
PEG—
EV/EBITDA-13.43
EV/Revenue6.30
P/S4.51
P/B-2.73
EPS (TTM)-2.09
EPS (Forward)1.44
52W Range
3.92050% of range18.31
52W High18.31 USD
52W Low3.920 USD
Profitability
Gross Margin87.09%
Oper. Margin-26.55%
EBITDA Margin-46.87%
Profit Margin-126.35%
ROE50.49%
ROA-85.37%
Growth
Revenue Growth104.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-166.78M USD
CapEx (TTM)229.00K USD
FCF Margin-37.84%
FCF Yield-8.71%
Net Debt366.31M USD
Net Debt/EBITDA-3.81
Balance Sheet
Debt/Equity-0.48
Current Ratio2.21
Quick Ratio2.09
Book Value/Sh-4.2420 USD
Cash/Share2.268 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)23.70 USD
Target Range13.00 USD – 29.00 USD
# Analysts10
Ownership
Shares Out.79.76M
Float60.43M
Insiders4.56%
Institutions88.49%
Short Interest
Short Ratio7.3d
Short % Float12.86%
Short % Out.12.21%
Shares Short9.74M
Short (prev mo.)10.64M
Technical
SMA 5011.73 (-4.9%)
SMA 20012.82 (-13.0%)
Beta0.57
S&P 52W Chg28.31%
Avg Vol (30d)1.28M
Avg Vol (10d)1.05M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—